Discover why some AML patients with monocytic differentiation don't respond to venetoclax+decitabine therapy and the emerging solutions to overcome this resistance.
Explore how TP53 mutation volume (VAF) is revolutionizing prognosis and treatment for acute myeloid leukemia patients through precision medicine approaches.
Exploring the Phase 1 clinical trial of voruciclib, a novel CDK9 inhibitor for relapsed/refractory AML and B-cell malignancies